Santen Pharmaceutical Co., Ltd.
4536
株式のランク
#4330
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research,... Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
株価
$11.35
最終同期: 2026-10-16
時価総額
$3.65B
変化（1日）
1.55%
変化（1年）
-0.91%
国
JP
取引 Santen Pharmaceutical Co., Ltd. (4536)
カテゴリー
Healthcare
の時価総額 Santen Pharmaceutical Co., Ltd.(4536)
時価総額: $3.65B
October 2026時点で、Santen Pharmaceutical Co., Ltd. の時価総額は $3.65B です。これは、当社のデータによると、Santen Pharmaceutical Co., Ltd. が世界で4330th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Santen Pharmaceutical Co., Ltd. の時価総額の履歴（2010 から 2026 まで）
